Skip to main content
Surgical Case Reports logoLink to Surgical Case Reports
. 2020 Feb 24;6:41. doi: 10.1186/s40792-020-0799-y

Sebaceous carcinoma of the breast predominantly characterized by intraductal growth: a case report

Koichi Ohno 1,, Toshihiro Okada 1, Toshitsugu Nakamura 2, Hiroshi Koyama 3
PMCID: PMC7040145  PMID: 32095941

Abstract

Background

Sebaceous carcinoma (SC) is frequently classified as periocular or extraocular. Extraocular SC is rare and mainly occurs in the head and neck, the major salivary glands, or oral mucosa. SC of the breast, lung, and ovary is particularly rare, and the few cases of SC of the breast predominantly exhibit intraductal growth.

Case presentation

A 47-year-old Japanese woman was referred to our hospital with accumulated polymorphic calcification in the left breast which was detected using mammography. Ultrasonography revealed an irregular 13-mm mass in the left breast, and analysis of a core needle biopsy revealed noninvasive ductal carcinoma. Total mastectomy and sentinel lymph node biopsy were performed. Histopathology demonstrated that carcinoma in situ (CIS) represented a significant lesion, and the cytoplasm of tumor cells was clear with numerous minute vacuoles. Immunohistochemical analysis demonstrated that most tumor cells expressed adipophilin. Together, these findings led to a diagnosis of SC, mainly comprising CIS.

Conclusions

We encountered a rare case of SC of the breast with predominant CIS.

Keywords: Breast carcinoma, Sebaceous carcinoma, Carcinoma in situ, Immunohistochemistry

Background

Sebaceous carcinoma (SC) is frequently classified as periocular or extraocular [1]. Extraocular SC is rare, occurring mainly in the head and neck, major salivary glands, oral mucosa, breasts, lungs, and ovaries [26]. Although carcinoma in situ (CIS) lesions of SC are rare, particularly associated with extraocular SC, they occur in the head, neck, and upper arm [710]. We are unaware of reports of SC of the breast with predominant CIS. For the first time to our knowledge, we report here a case of SC of the breast predominantly characterized by intraductal growth and review the relevant literature.

Case presentation

A 47-year-old Japanese woman presented with no subjective symptoms. Mammography revealed a clustered pleomorphic calcification in the left C region (Fig. 1a–d). She was referred to our hospital for further examinations. Her medical history stated that her mother had bilateral breast and ovarian cancers. Physical examination did not reveal a mass and papillary secretion in the breasts. The serum levels of the tumor markers carcinoembryonic antigen (CEA), CA15-3, NCC-ST-439, and BCA225 were normal. Ultrasonography identified a solid (13 mm × 12 mm × 7 mm), irregularly shaped low echo mass with a clear boundary in the left CD region and a high echo spot in the interior (Fig. 2). The findings of mammography and ultrasonography comprehensively classified the tumor as category 4, according to Breast Imaging Reporting and Data System (BI-RADS) 5th edition. Contrast-enhanced magnetic resonance imaging (MRI) revealed a lesion (14 mm × 11 mm × 12 mm) with clear margins in the left C region, confined to the same area (Fig. 3). Analysis of a core needle biopsy of this mass led to a diagnosis of ductal carcinoma in situ (DCIS), nuclear grade (NG) = 2, which was negative for the expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal receptor 2 (HER2). The Ki 67 labeling index was 32.4%. Positron emission tomography-computed tomography (PET-CT) revealed a breast tumor with a maximum standardized fluorodeoxyglucose (FDG) uptake value of 3.54 in the left C region. However, we did not detect an abnormal accumulation of FDG that would indicate metastasis to the axillary lymph nodes, lungs, liver, or bones (Fig. 4).

Fig. 1.

Fig. 1

Mammogram. Mammogram showing clustered pleomorphic calcification in the left MLO-M area (a) and CC-O area (b). c, d Enlargements of the areas indicated by yellow arrows

Fig. 2.

Fig. 2

Ultrasonography. Ultrasonography showing a hypoechoic irregular mass (13 mm × 12 mm × 7 mm) with clear roughening of the boundary and a high echo spot inside in the left CD area

Fig. 3.

Fig. 3

Contrast-enhanced magnetic resonance imaging (CE-MRI). CE-MRI showing an irregular mass with early arterial enhancement (14 mm × 11 mm × 12 mm) that was confined to the same area in the left C area

Fig. 4.

Fig. 4

Whole-body fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT). Whole-body FDG PET-CT images showing a mass in the left C area with a maximum standardized uptake value of 3.54 (yellow arrows). Other abnormal accumulations were not detected in other axillary lymph nodes, lungs, liver, and bones

Although hereditary breast and ovarian cancer syndrome (HBOC) could be considered a possibility because of the patient’s age and family history, she did not desire genetic counseling or BRCA testing. Upon the patient’s request, we performed total left mastectomy and sentinel lymph node biopsy (SLNB). SLNB was negative for metastasis and therefore axillary lymph node dissection was omitted. Macroscopic findings included a relative clear boundary and a yellowish white mass in the left C region, and continuity with the skin and papilla was not observed (Fig. 5a). Histopathology revealed stromal microinvasion (≤ 1-mm diameter) with predominant CIS. Numerous cells exhibited a clear and minute vacuolar cytoplasm, suggesting sebaceous differentiation (Fig. 5b, c). Immunohistochemical analysis revealed that 50 to 90% of the tumor cells expressed adipophilin (Fig. 5d, e), leading to a diagnosis of SC of the breast. The CIS lesions comprised tumor cells with similar phenotypes, and comedo necrosis was confirmed. Further tests did not detect venous or lymphatic invasion, NG = 3, or expression of ER-, PgR-, or HER2. The Ki 67 labeling index was 90% (Fig. 5f–j). Lymph node metastasis was not observed. Together, these findings were consistent with pathological T1mi, N0, M0 Stage I. The lesion was mainly CIS with minimal stromal invasion, and we therefore did not offer the patient chemotherapy. Metastasis or recurrence was not observed 16 months after surgery.

Fig. 5.

Fig. 5

Macroscopic and pathological findings. a Macroscopic analysis showing relatively clear boundaries. A localized yellowish, white mass was observed, and continuity between the skin and papilla was not evident. b Histopathological analysis revealed carcinoma in situ as the dominant lesion. Hematoxylin and eosin staining revealed cytoplasmic clear and minute vacuolar structures of numerous tumor cells, indicating sebaceous differentiation. c Higher magnification of b. d Most tumor cells (50–90%) were adipophilin-positive. e Higher magnification of d. fi Tumor cells did not detectably express estrogen receptor (ER), f progesterone receptor (PgR) (h), or human epidermal receptor 2 (HER2) (i). g Higher magnification of f. j The Ki 67 labeling index was 32.4%

Conclusions

SC is characterized by lobular forms or nests of tumor cells that exhibit sebaceous differentiation, which distinguishes SC from invasive ductal carcinoma (IDC) [11]. The World Health Organization classifies SC of the breast as primary breast carcinoma if at least half the constituent cells exhibit sebaceous differentiation and are not derived from cutaneous adnexal sebaceous glands as indicated by histopathological analysis [12]. Our present patient’s tumor originated deep within the mammary gland and was obviously separated from the adjoining skin. Further, lesions were present in the duct, which is consistent with our diagnosis of SC of the breast.

Published studies of SC of the breast do not establish its clinical significance. Thus, treatment typically follows that administered to patients with IDC.

Differential diseases of SC of the breast include histologically distinct glycogen-rich clear cell carcinomas and lipid-rich carcinomas. Glycogen-rich clear cell carcinomas typically become periodic acid-Shiff (PAS)-positive and therefore can be distinguished from SC cells because they do not produce glycogen [13]. Lipid-rich carcinoma is diagnosed according to the presence of tumor cells with a clear cytoplasm comprising at least 90% lipid-rich vacuoles [12]. Compared with SC of the breast, in which finely vacuolated cells grow into a compact lobulated solid form, the pattern of infiltration of lipid-rich carcinoma is similar to that of typical IDC and with much less conspicuous cellular vacuolization [14]. Thus, diagnosis is achieved through the demonstration of intracytoplasmic lipids detected using Oil Red O or Sudan Black B, or through immunohistochemical detection of the expression of adipophilin [15]. Because of its low incidence, there are no defined immunohistochemical features specific to SC of the breast, except for cytoplasmic lipids. Here, we found numerous clear cells with microvacuolar structures that we suspected to represent sebaceous differentiation. Further, 50–90% of the tumor cells were adipophilin-positive, which led to our diagnosis of SC of the breast.

Varga et al. [13], Ohara et al. [2], and Numoto et al. [16] propose hypotheses that explain the origin of SC of the breast, respectively, as follows: (a) The mammary glands of patients with breast cancer may exhibit features of sebaceous glands because these glands share the same origin. (b) SC of the breast develops from progenitor cells capable of differentiation into the sebaceous glands within the epithelium. (c) Sebaceous glands are ectopically present in the mammary gland.. If SC of the breast occurs in the absence of other breast cancer pathology, as is the case here, the possibility of scenarios b or c seems plausible.

A search of PubMed using the keywords “sebaceous carcinoma AND breast,” returned 16 case reports (Table 1) [4, 13, 14, 1624]. These results support our assertion that the present report is the first to identify a patient with pT1mi, N0, M0, Stage I SC of the breast with predominant CIS. As mentioned above, ocular SC is infrequently associated with CIS. Moreover, evidence indicates that CIS is rarely associated with extraocular SC, although extraocular SC occurs in the head and neck and upper arm [710]. We identified a fatal case in which metastasis occurred over a relatively short period of 28 months after treatment [14], a case where local recurrence occurred 10 months after partial mastectomy [22], and a case in which skin and bone metastasis occurred 96 months after treatment [13]. Further, we identified a patient who experienced disease-free survival for 75 months after surgery [14]. However, the aspects of our present unique case do not allow us to offer a prognosis. Our current patient was not administered postoperative chemotherapy, and we will therefore conduct a careful follow-up.

Table 1.

Survey of the literature describing the clinical and pathological features of sebaceous carcinoma of the breast

Authors Year Age Sex Surgery Pathological Findings
Breast Axillary node ER PgR AR HER2 Subtype NG Ki67 IDC component Adipophilin Oil red O Sudan Black B pT pN M Stage Prognosis
Prescott RJ 1992 74 F Bt Ax + + 2 0 X X AWNED, 6 months
Mazzella FM 1995 55 M Bt Ax + + Luminal 2 11 + + 2 0 X X AWNED, 10 months
Tavassoli FA 1999 46 F + Luminal 20 3 0 X X NA
Propeck PA 2000 46 F Tm→Bp 1 X X X AWEND, 6 months
Varga Z 2000 45 F Bt Ax + + Luminal 16 + 2 0 0 IIA→IV AWD, 96 months
Hisaoka M 2006 63 F Bt Ax + + Luminal 38 + 2 1 X X NA
Numoto S 2007 49 F Tm + + + Luminal 15 + 1 X X X NA
Murakami A 2009 50 F Bt Ax ± + HER2 30 + + 1 1 0 IIA AWNED, 24 months
Ramljak V 2010 85 F Bp→Bt TN 25 2 X X X AWD, 10 months
Kiyohara T 2013 76 F Bp SLNB 3 0 0 IIIA AWNED, 32 months
Svajdler M 2015 65 F Bp SLNB→Ax + + Luminal 3 30 + 1 1 0 IIA AWNED, 27 months
Svajdler M 2015 61 F Bt Ax TN 3 80 2 1 0 IIA→IV DOD, 28 months
Svajdler M 2015 66 F Bt Ax + Luminal 2 5 2 1 0 IIA→IV AWD, 70 months
Svajdler M 2015 25 F Bp Ax + + Luminal 3 X 0 X X AWNED, 75 months
Yamamoto Y 2017 80 F Bp SLNB TN 1 + + 2 0 0 IIA AWNED, 16 months
Ohno K 2019 47 F Bt SLNB TN 3 90 + 1mi 0 0 I AWNED, 16 months

Abbreviations: AR androgen receptor, Ax axillary dissection, AWD alive with disease, AWNED alive with no evidence of disease, Bp partial mastectomy, Bt total mastectomy, DOD died of disease, ER estrogen receptor, F female, HER2 human epidermal growth factor receptor type 2, IDC invasive ductal carcinoma, M male, NA not available, NG nuclear grade, PgR progesterone receptor, SLNB sentinel lymph node biopsy, Tm tumorectomy, TN triple negative

Change in surgery is indicated by an arrow

According to International Union Against Cancer TNM Classification of Malignant Tumors (8th Edition). Disease progression indicated by an arrow

In conclusion, here, we encountered a rare case of SC of the breast with predominant CIS. Although our findings contribute to our understanding of the pathogenesis, progression, and prognosis of SC of the breast, further studies of additional cases are required.

Acknowledgements

We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Abbreviations

AR

Androgen receptor

BI-RADS

Breast imaging reporting and data system

CEA

Carcinoembryonic antigen

CE-MRI

Contrast-enhanced magnetic resonance imaging

CIS

Carcinoma in situ

DCIS

Ductal carcinoma in situ

ER

Estrogen receptor

HBOC

Hereditary breast and ovarian cancer syndrome

HER2

Human epidermal receptor 2

IDC

Invasive ductal carcinoma

MRI

Magnetic resonance imaging

NG

Nuclear grade

PAS

Periodic acid-Shiff

PET-CT

Positron emission tomography-computed tomography

PgR

Progesterone receptor

SC

Sebaceous carcinoma

SLNB

Sentinel lymph node biopsy

Authors’ contributions

KO participated in the design of the study and drafted the manuscript. TO, TN, and HK helped to evaluate and interpret the clinical and pathological findings. All authors read and approved the final manuscript.

Funding

Not applicable

Availability of data and materials

The dataset supporting the conclusions of this article are available in the manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Koichi Ohno, Email: kohno@suwa.jrc.or.jp.

Toshihiro Okada, Email: t-okada@suwa.jrc.or.jp.

Toshitsugu Nakamura, Email: nakt5311@mvf.biglobe.ne.jp.

Hiroshi Koyama, Email: kan.yu.ryota@gmail.com.

References

  • 1.Knackstedt T, Samie FH. Sebaceous carcinoma: a review of the scientific literature. Curr Treat Options Oncol. 2017;18:47. doi: 10.1007/s11864-017-0490-0. [DOI] [PubMed] [Google Scholar]
  • 2.Ohara N, Taguchi K, Yamamoto M, Nagano T, Akagi T. Sebaceous carcinoma of the submandibular gland with high-grade malignancy: report of a case. Pathol. Int. 1998;48:287–291. doi: 10.1111/j.1440-1827.1998.tb03907.x. [DOI] [PubMed] [Google Scholar]
  • 3.Siriwardena BS, Tilakaratne WM, Rajapakshe RM. A case of sebaceous carcinoma of the parotid gland. J Oral Pathol Med. 2003;32:121–123. doi: 10.1034/j.1600-0714.2003.00037.x. [DOI] [PubMed] [Google Scholar]
  • 4.Prescott RJ, Eyden BP, Reeve NL. Sebaceous differentiation in a breast carcinoma with ductal, myoepithelial and squamous elements. Histopathology. 1992;21:181–184. doi: 10.1111/j.1365-2559.1992.tb00371.x. [DOI] [PubMed] [Google Scholar]
  • 5.Borczuk AC, Sha KK, Hisler SE, Mann JM, Hajdu SI. Sebaceous carcinoma of the lung: histologic and immunohistochemical characterization of an unusual pulmonary neoplasm: report of a case and review of the literature. Am J Surg Pathol. 2002;26:795–798. doi: 10.1097/00000478-200206000-00015. [DOI] [PubMed] [Google Scholar]
  • 6.Vartanian RK, McRae B, Hessler RB. Sebaceous carcinoma arising in a mature cystic teratoma of the ovary. Int J Gynecol Pathol. 2002;21:418–421. doi: 10.1097/00004347-200210000-00014. [DOI] [PubMed] [Google Scholar]
  • 7.Oka K, Katsumata M. Intraepidermal sebaceous carcinoma: case report. Dermatologica. 1990;180:181–185. doi: 10.1159/000248026. [DOI] [PubMed] [Google Scholar]
  • 8.Ansai S, Mihara I. Sebaceous carcinoma arising on actinic keratosis. Eur J Dermatol. 2000;10:385–388. [PubMed] [Google Scholar]
  • 9.Ansai S, Takeichi H, Arase S, Kawana S, Kimura T. Sebaceous carcinoma: an immunohistochemical reappraisal. Am J Dermatopathol. 2011;33:579–587. doi: 10.1097/DAD.0b013e31820a2027. [DOI] [PubMed] [Google Scholar]
  • 10.Aung PP, Batrani M, Mirzabeigi M, Goldberg LJ. Extraocular sebaceous carcinoma in situ: report of three cases and review of the literature. J Cutan Pathol. 2014;41:592–596. doi: 10.1111/cup.12351. [DOI] [PubMed] [Google Scholar]
  • 11.Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma--rare types: review of the literature. Ann Oncol. 2009;20:1763–1770. doi: 10.1093/annonc/mdp245. [DOI] [PubMed] [Google Scholar]
  • 12.Eusebi V, Ichihara S, Vincent-Salomon A, Sneige N, Sapino A. Exceptionally rare types and variants. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO classification of tumours of the breast. 4. Lyon: IARC; 2012. pp. 71–76. [Google Scholar]
  • 13.Varga Z, Kolb SA, Flury R, Burkhard R, Caduff R. Sebaceous carcinoma of the breast. Pathol Int. 2000;50:63–66. doi: 10.1046/j.1440-1827.2000.01003.x. [DOI] [PubMed] [Google Scholar]
  • 14.Svajdler M, Banik P, Poliakova K, Straka L, Hribikova Z, Kinkor Z, et al. Sebaceous carcinoma of the breast: report of four cases and review of the literature. Pol J Pathol. 2015;66:142–148. doi: 10.5114/pjp.2015.53010. [DOI] [PubMed] [Google Scholar]
  • 15.Ostler DA, Prieto VG, Reed JA, Deavers MT, Lazar AJ, Ivan D. Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. Mod Pathol. 2010;23:567–573. doi: 10.1038/modpathol.2010.1. [DOI] [PubMed] [Google Scholar]
  • 16.Numoto S, Iwata J, Nakai T, Aki F. A case of sebaceous carcinoma of the breast. Jpn J Diagn Pathol. 2007;24:58–61. [Google Scholar]
  • 17.Mazzella FM, Sieber SC, Braza F. Ductal carcinoma of male breast with prominent lipid-rich component. Pathology. 1995;27:280–283. doi: 10.1080/00313029500169123. [DOI] [PubMed] [Google Scholar]
  • 18.Tavassoli FA. Sebaceous carcinoma. In: Medina MP, Greenfield S, editors. Pathology of the breast. 2. Stamford: Appleton and Lange; 1999. pp. 555–558. [Google Scholar]
  • 19.Propeck PA, Warner T, Scanlan KA. Sebaceous carcinoma of the breast in a patient with Muir-Torre syndrome. Am J Roentgenol. 2000;174:541–542. doi: 10.2214/ajr.174.2.1740541. [DOI] [PubMed] [Google Scholar]
  • 20.Hisaoka M, Takamatsu Y, Hirano Y, Maeda H, Hamada T. Sebaceous carcinoma of the breast: case report and review of the literature. Virchows Arch. 2006;449:484–488. doi: 10.1007/s00428-006-0264-8. [DOI] [PubMed] [Google Scholar]
  • 21.Murakami A, Kawachi K, Sasaki T, Ishikawa T, Nagashima Y, Nozawa A. Sebaceous carcinoma of the breast. Pathol Int. 2009;59:188–192. doi: 10.1111/j.1440-1827.2009.02349.x. [DOI] [PubMed] [Google Scholar]
  • 22.Ramljak V, Sarcevic B, Vrdoljak DV, Kelcec IB, Agai M, Ostovic KT. Fine needle aspiration cytology in diagnosing rare breast carcinoma--two case reports. Coll Antropol. 2010;34:201–205. [PubMed] [Google Scholar]
  • 23.Kiyohara T, Tokuriki A, Kanamori Y, Yasuta M, Imamura Y, Kumakiri M. Superficial sebaceous carcinoma on the areola clinically mimicking mammary Paget’s disease. J Dermatol. 2013;40:145–147. doi: 10.1111/1346-8138.12010. [DOI] [PubMed] [Google Scholar]
  • 24.Yamamoto Y, Nakamura T, Koyama H, Kanai T, Moritani S, Ichihara S. Sebaceous carcinoma of the breast: a case report. J Surg Case Rep. 2017;3:38. doi: 10.1186/s40792-017-0312-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The dataset supporting the conclusions of this article are available in the manuscript.


Articles from Surgical Case Reports are provided here courtesy of Springer-Verlag

RESOURCES